불임 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Infertility Drugs Market size is expected to reach USD 7.58 Billion in 2034 from USD 4.36 Billion (2025) growing at a CAGR of 6.34% during 2026-2034.

The Global Infertility Drugs Market is witnessing significant growth as infertility rates continue to rise worldwide. Lifestyle changes, delayed pregnancies, and increasing prevalence of reproductive health disorders are major factors contributing to infertility among both men and women. Infertility drugs are widely used in assisted reproductive treatments to stimulate ovulation and improve the chances of successful conception.

Advancements in reproductive medicine and increasing awareness about fertility treatments are driving demand for infertility drugs. Healthcare providers are offering a wide range of pharmaceutical treatments as part of fertility therapy programs, including hormone therapies and ovulation induction medications. In addition, the expansion of fertility clinics and improved access to assisted reproductive technologies are supporting market growth.

Looking ahead, the Global Infertility Drugs Market is expected to grow as research in reproductive medicine continues to advance. Pharmaceutical companies are developing innovative drug formulations that improve treatment outcomes and reduce side effects. With increasing awareness about fertility health and expanding fertility treatment services, the market for infertility drugs is projected to experience sustained growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Gonadotropins
• Aromatase Inhibitors
• Selective Estrogen Receptor Modulators (SERMs)
• Dopamine Agonists
• Others

By Distribution Channel

• Hospital Pharmacy
• Specialty & Retail Pharmacy
• Online Pharmacy

By End-user

• Men
• Women

COMPANIES PROFILED

• Merck Co Inc, Ferring BV, Organon Group of Companies, Abbott, Novartis AG, Bayer AG, Pfizer Inc, Mankind Pharma, Teva Pharmaceutical Industries LTD, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL INFERTILITY DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Gonadotropins Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Aromatase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Selective Estrogen Receptor Modulators (SERMs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Dopamine Agonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL INFERTILITY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Specialty & Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL INFERTILITY DRUGS MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Men Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Women Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL INFERTILITY DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Distribution Channel
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Distribution Channel
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Distribution Channel
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Distribution Channel
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Distribution Channel
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL INFERTILITY DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Merck & Co. Inc
  • 9.2.2 Ferring B.V
  • 9.2.3 Organon Group Of Companies
  • 9.2.4 Abbott
  • 9.2.5 Novartis AG
  • 9.2.6 Bayer AG
  • 9.2.7 Pfizer Inc
  • 9.2.8 Mankind Pharma
  • 9.2.9 Teva Pharmaceutical Industries LTD
  • 9.2.10 Sanofi